Goserelin (Zoladex) is a synthetic GnRH agonist — a drug that suppresses sex hormone production — used to treat hormone-sensitive cancers of the prostate and breast, endometriosis, and dysfunctional uterine bleeding.
What it does
Goserelin mimics gonadotropin-releasing hormone (GnRH), the signal the hypothalamus sends to the pituitary gland to trigger release of LH and FSH — the hormones that tell the testes and ovaries to make testosterone and estrogen. The catch: when GnRH receptors in the pituitary are stimulated continuously rather than in the normal pulsatile bursts, they desensitize and shut down. Within two to four weeks of starting goserelin, LH and FSH levels fall sharply, and sex hormone levels drop to castrate range NCT00841113.
This hormonal suppression is the therapeutic goal. Prostate cancer cells typically depend on testosterone to grow; breast cancer cells in premenopausal women depend on estrogen. Strip away those signals and tumor growth slows or reverses. In animal models, goserelin caused regression of both dimethylbenzanthracene-induced mammary tumors and Dunning R3327 prostate tumors NCT04356430. The same logic applies to endometriosis — a condition where estrogen-driven tissue grows outside the uterus — and to thickening of the uterine lining before ablation procedures.
What the evidence shows
Prostate cancer (locally confined, Stage B2-C) Well-established clinical indication; combination protocol supported by randomized trial data
Goserelin combined with an antiandrogen (flutamide or bicalutamide) and radiation is a standard approach for locally advanced prostate cancer. The protocol calls for starting hormonal therapy 8 weeks before radiation and continuing through treatment, a timing design supported by studies showing improved tumor control compared to radiation alone NCT00841113. Active trials continue comparing GnRH agonists like goserelin head-to-head with newer androgen-deprivation strategies NCT04356430.
Advanced prostate cancer (palliative) Established palliative indication; long clinical track record
For metastatic or advanced prostate cancer where cure is not the goal, goserelin reduces testosterone to castrate levels and reliably slows disease progression and eases symptoms such as bone pain. It does not eliminate the cancer but can meaningfully extend time before disease worsens NCT00841113.
Advanced breast cancer (pre- and perimenopausal, palliative) Established indication; clinical trial data support use in hormone-receptor-positive disease
In pre- and perimenopausal women with hormone-receptor-positive advanced breast cancer, goserelin suppresses ovarian estrogen production and can slow tumor progression. This is a palliative indication — it extends and improves quality of life rather than offering cure. Evidence from clinical programs incorporating GnRH agonists in hormonal manipulation strategies is well documented NCT04356430.
Endometriosis Approved indication; randomized trial support for symptom relief
By suppressing estrogen, goserelin induces a temporary, reversible hypoestrogenic state that causes endometrial implants (patches of uterine-like tissue growing outside the uterus) to shrink and become less active. Pain and lesion burden improve during treatment, though symptoms can return after stopping. Use is generally limited to six months due to bone density loss.
Endometrial thinning before ablation Approved procedural indication
A single or short course of goserelin suppresses estrogen enough to thin the uterine lining before endometrial ablation (a procedure that destroys the lining to treat heavy uterine bleeding), making the procedure more technically straightforward and effective NCT04356430.
Androgen receptor-positive salivary gland carcinoma Early-phase investigational; limited data
Some rare salivary gland cancers express androgen receptors, and researchers are investigating whether GnRH agonist-based androgen deprivation can slow their growth. This is an active area of exploration rather than an established use NCT04325828.
How it's used
In approved clinical protocols, goserelin is administered as a subcutaneous (under the skin) implant injected into the anterior abdominal wall. The standard dose is 3.6 mg every 28 days; a 10.8 mg depot formulation dosed every 12 weeks is used for some prostate cancer indications. Duration depends heavily on indication — endometriosis treatment is typically capped at six months to limit bone loss, while cancer indications may involve indefinite ongoing therapy. Timing relative to other treatments (radiation, surgery, antiandrogens) matters clinically and varies by protocol. In studies, the combination with flutamide for prostate cancer begins 8 weeks before radiation NCT00841113.
Side effects and safety
Side effects follow directly from sex hormone suppression. In men: hot flashes, reduced libido, erectile dysfunction, fatigue, and breast tissue growth (gynecomastia). In women: hot flashes, vaginal dryness, mood changes, and depression. Edema (fluid retention) and headaches are reported across both sexes. With chronic use, the most serious concern is bone mineral density loss — goserelin induces a state comparable to surgical castration or menopause, and prolonged low estrogen or testosterone accelerates bone thinning and raises fracture risk. Cardiovascular events including QT prolongation and increased risk of myocardial infarction and stroke have been reported in men on long-term androgen deprivation; baseline cardiovascular risk should factor into treatment decisions. Goserelin is contraindicated in pregnancy (except in the specific context of palliative breast cancer treatment) and should be used with caution in patients with existing osteoporosis, cardiovascular disease, or a history of blood clots. Long-term effects in younger patients used off-label remain incompletely characterized.
Bottom line
Goserelin is a well-studied hormonal therapy with decades of clinical use and solid evidence behind its approved indications — prostate cancer, hormone-sensitive breast cancer, and endometriosis. The tradeoffs are real: bone loss, cardiovascular risk, and hormonal side effects are not minor. It belongs in a supervised clinical setting, not self-directed use.